Research

PsiKick is utilizing revolutionary ultra-low-power technologies from the Universities of Virginia and Michigan to build completely self-powered sensing systems that do not require batteries, can be deployed nearly anywhere, and unlock new data stream

A WMRA podcast alludes to UVA's role in the biotechnology industry in Central Virginia.

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

The CvilleBioHub has been awarded over $80,000 from the GO Virginia initiative to expand and sustain the biotechnology ecosystem in the region.

UVA researchers propose that the business community can address sustainability challenges through innovation and development of new technologies.

UVA and UVA-Wise are considering recommendations for improving challenges faced by rural Virginians. The initiative is engaging additional Virginia colleges and universities, government agencies, and stakeholders across the state.

Industry clusters are groups of firms that gain a competitive advantage by co-locating in a geographic region and sharing assets, networks, knowledge, workforce training, etc. The Office of Economic Development partners with allies to help support…

UVA was named a National Science Foundation I-Corps Site—one of 89 such sites at universities in the nation—to help entrepreneurs consider customer feedback in developing ideas that are relevant to society and exhibit applications for commerciali

UVA supports regional commercialization, investing directly in companies that take the University’s research and intellectual property to market and increasing the pace for new medical products that improve the health of Virginians and beyond.